Formulation Development & Manufacturing - Special feature in DRUG DEVELOPMENT & DELIVERY

Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs (published in DRUG DEVELOPMENT & DELIVERY)

Quality has always been a key priority for the pharmaceutical industry. Over the last years there has been a trend to tackling quality upfront in the pharmaceutical manufacturing process. By using approaches such as Quality by Design (QbD), quality is already considered during formulation development rather than waiting until the product is designed and then deciding how quality will be assured. Dr. Martin Koeberle, Head of Analytical Development & Stability Testing at HERMES is convinced that this approach makes sense – after all, quality can’t be tested into a product, it needs to be there by design.

See more at: http://www.drug-dev.com/Main/Back-Issues/SPECIAL-FEATURE-Formulation-Development-Manufactur-1296.aspx